Researcher profile

Amanda Cano

Dr. Amanda Cano is currently the head of the Molecular Biology & Biomarkers program of the research department of Ace Alzheimer Center Barcelona. Previously, she was an adjunct professor of Physical Chemistry at the University of Barcelona. She graduated from Pharmacy at the University of Salamanca and received her master’s degree from the University of Barcelona. Her PhD studies were focused on nanomedicine and neurosciences, obtaining the doctoral degree from the University of Barcelona. In this period, she also combined experimental activity with teaching experience. She carried out several international research stays at the Massachusetts Institute of Technology in the USA, the University College of London in the United Kingdom, the University of Modena and Reggio Emilia in Italy, and the University of Trás-os-Montes and Alto Douro in Portugal. She is a member of the International Society to Advance Alzheimer’s Research and Treatment (ISTAART, Alzheimer’s Association), the Institute of Nanoscience and Nanotechnology (IN2UB), Grupo Español de Investigación e Innovación en Vesiculas Extracelulares (GEIVEX), and the Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED). She has obtained several competitive fellowships to develop her scientific career, and possess the official credentials of Assistant Professor of the National Agency for Evaluation and Accreditation (ANECA) of the Ministry of Science (Spanish government), and the Agency for the Quality of the University System of Catalonia (AQU) (Generalitat of Catalunya). She has participated in several competitive European projects, competitive national projects, and non-competitive national and international projects. Her postdoctoral studies were related to the clinical evaluation of fluid biomarkers in the early stages of Alzheimer’s disease. Likewise, she has participated as a pharmacist in multiple clinical trials at the Ace Alzheimer Center Barcelona. Currently, her research focuses on the identification and evaluation of new biomarkers and molecular routes involved in the neuropathological development of the Alzheimer’s disease, through the development of proteomic, lipidomic and metabolomic analysis in representative human's samples of the different stages of the disease continuum.